We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alternate Day Buprenorphine Administration, Phase IX - 14

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000232
First Posted: September 21, 1999
Last Update Posted: May 6, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont
  Purpose
The purpose of this study is to determine if four times a subjects' daily maintenance dose will hold for 120 hours without changes in agonist and antagonist effects.

Condition Intervention Phase
Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Alternate Day Buprenorphine Administration, Phase IX

Resource links provided by NLM:


Further study details as provided by University of Vermont:

Primary Outcome Measures:
  • Drug use
  • Opioid withdrawal
  • Opioid agonist effects
  • Dose identification
  • Pupil diameter

Estimated Enrollment: 0
Study Start Date: March 1992
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 51 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000232


Locations
United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information

ClinicalTrials.gov Identifier: NCT00000232     History of Changes
Other Study ID Numbers: NIDA-06969-14
R01DA006969 ( U.S. NIH Grant/Contract )
R01-06969-14
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: May 6, 2016
Last Verified: April 1994

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists